ADVERTISEMENT
Advertise

Content

List volumes - List articles in this issue

Clinical Report

Antiviral Therapy in Children with Hydroa Vacciniforme

doi: 10.2340/00015555-0670

Abstract:

Hydroa vacciniforme is a rare, usually quite severe, photo­dermatosis. Association with Epstein-Barr virus infection and a possibly increased risk of lymphoprolifera­tive malignancy have been demonstrated. We describe here four patients with Epstein-Barr virus-associated hydroa vacciniforme treated with acyclovir/valacyclovir therapy with a good clinical response. The children were reported to have less fatigue, fewer eruptions, less scarring, and increased ability to spend time outdoors without provoking new eruptions. This was also in agreement with clinical observations. However, one patient progressed into an anaplastic lymphoma kinase-1-negative anaplastic large-cell lymphoma in the upper jaw. This was preceded by an increase in EBV viral load. Acyclovir/valacyclovir therapy is a safe treatment. Further studies are required to confirm these results.

Authors:

Josefin Lysell, Desiree Wiegleb Edström, Annika Linde, Göran Carlsson, Johan Malmros-Svennilson, Anders Westermark, Jan Andersson and Carl-Fredrik Wahlgren

References

  • Gupta G, Man I, Kemmett D. Hydroa vacciniforme: a clinical and follow-up study of 17 cases. J Am Acad Dermatol 2000; 42: 208–213.
  • Goldgeier MH, Nordlund JJ, Lucky AW, Sibrack LA, McCarthy MJ, McGuire J. Hydroa vacciniforme: diagnosis and therapy. Arch Dermatol 1982; 118: 588–591.
  • Iwatsuki K, Satoh M, Yamamoto T, Oono T, Morizane S, Ohtsuka M, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol 2006; 142: 587–595.
  • Iwatsuki K, Xu Z, Takata M, Iguchi M, Ohtsuka M, Akiba H, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999; 140: 715–721.
  • Ohtsuka T, Okita H, Otsuka S, Yamakage A, Yamazaki S. Hydroa vacciniforme with latent Epstein-Barr virus infection. Br J Dermatol 2001; 145: 509–510.
  • Linde A, Andersson J, Lundgren G, Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol 1987; 21: 109–121.
  • Linde A, Kallin B, Dillner J, Andersson J, Jagdahl L, Lindvall A, et al. Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis 1990; 161: 903–909.
  • Cho KH, Kim CW, Lee DY, Sohn SJ, Kim DW, Chung JH. An Epstein-Barr virus-associated lymphoproliferative lesion of the skin presenting as recurrent necrotic papulovesicles of the face. Br J Dermatol 1996; 134: 791–796.
  • Magana M, Sangueza P, Gil-Beristain J, Sanchez-Sosa S, Salgado A, Ramon G, et al. Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like lymphoma): a distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 574–579.
  • Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002; 10: 7–14.
  • Tynell E, Aurelius E, Brandell A, Julander I, Wood M, Yao QY, et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis 1996; 174: 324–331.
  • Keever-Taylor CA, Behn B, Konings S, Orentas R, Davies B, Margolis D. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. Cytotherapy 2003; 5: 323–335.
  • Balfour HH, Jr., Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol 2007; 39: 16–21.
  • Gruhn B, Meerbach A, Hafer R, Zell R, Wutzler P, Zintl F. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1023–1025.
  • Yesudian PD, Sharpe GR. Hydroa vacciniforme with oral mucosal involvement. Pediatr Dermatol 2004; 21: 555–557.
  • Rhodes LE, White SI. Dietary fish oil as a photoprotective agent in hydroa vacciniforme. Br J Dermatol 1998; 138: 173–178.
  • Slots J, Saygun I, Sabeti M, Kubar A. Epstein-Barr virus in oral diseases. J Periodontal Res 2006; 41: 235–244.
  • Related articles

    There are no related articles.


    Share with your friends





    Actions


    Abstract

    Full text

    PDF

    Supplementary


    There is no supplementary for this article.

    Print information


    Volume 89, Issue 4

    DOI: 10.2340/00015555-0670

    Pages: 393-397

    View at PubMed